MARKET

PHAS

PHAS

PhaseBio Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.730
+0.160
+3.50%
After Hours: 4.800 +0.07 +1.48% 18:46 07/10 EDT
OPEN
4.600
PREV CLOSE
4.570
HIGH
4.980
LOW
4.420
VOLUME
358.72K
TURNOVER
--
52 WEEK HIGH
11.55
52 WEEK LOW
2.600
MARKET CAP
136.13M
P/E (TTM)
-2.8861
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PHAS stock price target is 15.67 with a high estimate of 18.00 and a low estimate of 11.00.

EPS

PHAS News

More
What You Need To Know About The PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) Analyst Downgrade Today
Simply Wall St. · 11h ago
3 Coronavirus Penny Stocks With Triple-Digit Upside Potential
TipRanks · 6d ago
Hedge Funds Are Selling PhaseBio Pharmaceuticals, Inc. (PHAS)
Insider Monkey · 06/16 01:51
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More
Zacks · 06/03 14:56
50 Stocks Moving In Tuesday's Mid-Day Session
Gainers Tenax Therapeutics Inc (NASDAQ: TENX) shares climbed 42.3% to $2.07 after the company reported results from its Phase 2 trial of Levosimendan. The trial demonstrated a significant reduction in right atrial and pulmonary capillary wedge pressures.
Benzinga · 06/02 16:21
CGC, DXC among premarket losers
Seeking Alpha - Article · 05/29 13:20
65 Biggest Movers From Yesterday
Gainers ARCA biopharma, Inc. (NASDAQ: ABIO) shares climbed 386.3% to close at $19.21 on Thursday after the company announced the development program for its AB201 treatment of coronavirus associated with coagulopathy.
Benzinga · 05/29 09:35
Mid-Afternoon Market Update: Dow Rises 150 Points; Triumph Group Shares Spike Higher
Toward the end of trading Thursday, the Dow traded up 0.61% to 25,704.71 while the NASDAQ rose 0.81% to 9,488.49. The S&P also rose, gaining 0.84% to 3,061.53.
Benzinga · 05/28 18:35

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About PHAS

Phasebio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The Company’s lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor, which the Company is developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. Its product candidate, PB1046, is a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, or PAH. PB1046 utilizes its proprietary elastin-like polypeptide (ELP), technology, which also serves as the engine for its preclinical pipeline. Its ELP biopolymer technology utilizes a mechanism of slow absorption through a reversible phase transition and a prolonged circulatory half-life.
More

Webull offers kinds of PhaseBio Pharmaceuticals Inc stock information, including NASDAQ:PHAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHAS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PHAS stock methods without spending real money on the virtual paper trading platform.